| Code | CSB-RA003657MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to sutimlimab, targeting C1s (complement component 1s), a serine protease within the classical complement pathway. C1s functions as the enzymatic subcomponent of the C1 complex, cleaving C4 and C2 to initiate the complement cascade. This protease plays a critical role in immune-mediated hemolytic conditions, particularly cold agglutinin disease (CAD), where aberrant complement activation leads to red blood cell destruction. Dysregulated C1s activity has also been implicated in various autoimmune disorders and complement-mediated pathologies.
Sutimlimab represents a first-in-class C1s inhibitor that selectively blocks classical pathway activation while preserving lectin and alternative pathway functions. This biosimilar antibody provides researchers with a valuable tool for investigating complement-mediated mechanisms in hemolytic anemias, autoimmune diseases, and inflammatory conditions. It enables studies of C1s-specific inhibition in disease models and facilitates exploration of therapeutic strategies targeting the classical complement pathway. The antibody supports diverse immunological research applications examining complement regulation and immune system modulation.
There are currently no reviews for this product.